Walmart is set to join the Nasdaq-100 Index, replacing British pharmaceutical giant AstraZeneca, as part of an index rebalancing effective before the market opens on January 20, according to a statement released by Nasdaq. This move follows Walmart’s earlier announcement in November that it would shift its primary stock listing from the New York Stock Exchange (NYSE) to Nasdaq, marking a significant change for the world’s largest retailer after decades on the NYSE.
The inclusion of Walmart in the Nasdaq-100 Index underscores the growing appeal of Nasdaq as a listing venue for large, high-profile companies. The Nasdaq-100 Index tracks 100 of the most valuable non-financial companies listed on the Nasdaq exchange and includes global leaders such as Apple, Nvidia, Microsoft, and Amazon. In addition to the main index, Walmart will also be added to the Nasdaq-100 Equal Weighted Index and the Nasdaq-100 Ex-Tech Sector Index, further expanding its presence across Nasdaq’s flagship benchmarks.
Companies often decide to change listing venues when they believe another exchange offers better alignment with their investor base, advanced trading technology, enhanced services, or lower listing and compliance costs. In recent years, Nasdaq has positioned itself as an attractive platform not only for technology companies but also for major consumer, healthcare, and industrial firms seeking broader exposure and index inclusion.
Several companies that moved from the NYSE to Nasdaq in 2025 cited the growing prestige and visibility of the Nasdaq-100 Index as a key factor in their decision. Being part of the index can lead to increased demand from index-tracking funds and institutional investors, potentially boosting liquidity and long-term shareholder value.
For Walmart, the transition represents more than a symbolic shift. It aligns the retail giant with a group of globally influential companies and reflects its evolving business model, which increasingly integrates e-commerce, technology, and data-driven operations. Meanwhile, AstraZeneca’s removal highlights the competitive and dynamic nature of major stock indices, where changes in market capitalization and listings can quickly reshape index composition.


Bank of America's $72.5M Epstein Settlement: What You Need to Know
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Apple Turns 50: From Garage Startup to AI Crossroads
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



